Steffen Lang

Title: Steffen Lang: Innovator in Pharmaceutical Development

Introduction

Steffen Lang is a notable inventor based in Reinach, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the preparation of pharmaceutical products and compositions. With a total of 2 patents, Lang's work is recognized for its innovative approaches to drug formulation.

Latest Patents

Lang's latest patents include a method for preparing a pharmaceutical product. This method involves several steps, including providing a neat active pharmaceutical ingredient (API) that meets specific parameters determined by a FT4 powder rheometer. The parameters include a specific basic flow energy of at most 60 mJ/g and a stability index ranging from 0.75 to 1.25, among others. The process also involves dispensing the neat API into a pharmaceutical carrier and encapsulating it to produce the final product. Another patent focuses on spontaneously dispersible pharmaceutical compositions that include a piperidine, specifically a 1-acylpiperidine Substance P Antagonist, which is used in treating CNS disorders such as depression and social phobia, as well as respiratory diseases like asthma and chronic bronchitis.

Career Highlights

Steffen Lang is currently employed at Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to apply his innovative ideas in a practical setting, contributing to the development of new pharmaceutical solutions.

Collaborations

Throughout his career, Lang has collaborated with notable colleagues, including Kurt Liechti and Elodia Di Renzo. These collaborations have further enhanced his research and development efforts in the pharmaceutical industry.

Conclusion

Steffen Lang's contributions to pharmaceutical innovation demonstrate his commitment to improving healthcare through advanced drug formulation techniques. His patents reflect a deep understanding of pharmaceutical science and a dedication to addressing complex medical challenges.